Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Florent says an MDR contains registration, product and event information that already exists; only the manufacturer response and event description need careful judgment. Smartiva demonstrated a three-minute AI-assisted MDR submission so customers can spend time on patient safety and product improvement instead of filling out forms.

Related Insights

Florent describes the ideal complaint check: match the issue to a hazard in the risk file, find the acceptable failure rate, count similar events over 12 months, then divide by sales or install base. Nobody does this because gathering and correlating the data is too much work; Smartiva's AI does it in real time.

The primary bottlenecks in getting MedTech products to market are operational, not scientific. Tasks like reviewing regulations and preparing documentation are so mundane and laborious that they lead to human error and a waste of talent. AI is best suited to solve these operational pain points.

AI delivers the most value when applied to mature, well-understood processes, not chaotic ones. Pharma's MLR (Medical, Legal, Regulatory) review is a prime candidate for AI disruption precisely because its established, structured nature provides the necessary guardrails and historical data for AI to be effective.

Traditional data managers spend substantial time manually comparing records across disparate electronic data capture and safety platforms. Agentic workflows automate data assembly and reconciliation, enabling managers to focus on resolving complex clinical discrepancies and expediting database locks.

Florent says complaints, adverse events, field service and repairs are continuous signals from the field. Most medical device companies only collect that data; the missing piece is recognizing signals from noise and taking action. That gap makes recalls look like visibility failures, not just isolated engineering failures.

The FDA has adopted AI systems like ELSA and Halo to review submissions. To achieve a successful review, companies must now match the FDA's capabilities by using their own AI tools, assisted by human experts, to prepare documentation, effectively leveling the playing field.

AI adoption in drug companies isn't about moonshot discovery via a single prompt. Its immediate, high-impact use is in automating and error-proofing massive regulatory documents for the FDA, where a single misplaced comma can cause costly, multi-billion dollar delays.

The MLR process is not a single review step but a six-stage journey: content submission, internal readiness check, the MLR review, final sign-off, health authority submission, and expiration management. Recognizing this granularity reveals distinct automation opportunities at each stage beyond the review itself.

Pharmaceutical giants are adopting AI not for moonshot "cure cancer" prompts, but to streamline critical, error-prone processes like compiling 10,000-page FDA documents. This mundane application prevents costly delays and accelerates time-to-market for multi-billion dollar drugs.

AI tools can be rapidly deployed in areas like regulatory submissions and medical affairs because they augment human work on documents using public data, avoiding the need for massive IT infrastructure projects like data lakes.